Focus: Poseida Therapeutics is a San Diego-based genome editing biotech specializing in CAR-T cell therapies for oncology and neurology. The company operates as a pre-revenue clinical-stage developer with a focused pipeline in cell immunotherapy.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Recent layoff filing — 52 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Poseida Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Poseida Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Poseida Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Poseida Therapeutics stock (US74020J1025): cash-and-stock merger puts gene therapy player in focus - AD HOC NEWS
Poseida Therapeutics stock (US74020J1025): cash-and-stock merger puts gene therapy player in focus AD HOC NEWS
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid The Manila Times
8-K Filing: ALX ONCOLOGY HOLDINGS INC (ALXO) (CIK 0001810182) — EX-99.1
EX-99.1
8-K Filing: First Tracks Biotherapeutics, Inc. (TRAX) (CIK 0002091349) — EX-99.1
EX-99.1
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No public regulatory or compliance warnings detected, but absence of hiring and undisclosed financials suggest operational constraints.
Recent peer-reviewed publications with author affiliations at this company
A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone.
Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo